<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156646</url>
  </required_header>
  <id_info>
    <org_study_id>WP41047</org_study_id>
    <nct_id>NCT04156646</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers</brief_title>
  <official_title>A Single-Center, Part-Randomized, Open-Label, Single-Dose, Three-Period, Crossover Study to Investigate the Effect of Esomeprazole and The Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effect of food and the effect of esomeprazole on the
      pharmacokinetics (PK) of a single dose of balovaptan in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Actual">January 6, 2020</completion_date>
  <primary_completion_date type="Actual">December 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time Extrapolated to Infinity (AUC (0-inf)) of balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC(0-24h)) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16 and 24 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Cmax in Plasma (Tmax) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Last Quantifiable Concentration (Clast) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time To the Last Quantifiable Concentration (Tlast) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Between Dosing and Time of First Balovaptan Plasma Concentration (Tlag)</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (Cl/F) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Phase Half-Life (T1/2) of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of Balovaptan</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time Extrapolated to Infinity (AUC (0-inf)) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time Extrapolated to Infinity (AUC (0-inf)) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time Extrapolated to Infinity (AUC (0-inf)) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC(0-24h)) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16 and 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC(0-24h)) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16 and 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC(0-24h)) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax in Plasma (Tmax) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax in Plasma (Tmax) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax in Plasma (Tmax) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last Quantifiable Concentration (Clast) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last Quantifiable Concentration (Clast) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last Quantifiable Concentration (Clast) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To the Last Quantifiable Concentration (Tlast) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To the Last Quantifiable Concentration (Tlast) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To the Last Quantifiable Concentration (Tlast) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (Cl/F) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (Cl/F) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (Cl/F) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Phase Half-Life (T1/2) of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Phase Half-Life (T1/2) of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Phase Half-Life (T1/2) of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patricipants with Adverse Events (AEs)</measure>
    <time_frame>Randomization to end of study (up to approximately 11 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of M2 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of M3 Metabolite</measure>
    <time_frame>Samples at predose, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48, 72, 96, 144, and 192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Esomeprazole</measure>
    <time_frame>Samples at predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balovaptan</intervention_name>
    <description>Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No evidence of any active or chronic disease

          -  Body mass index (BMI) between 18 and 32 kg/m2 inclusive, at screening

          -  For women of childbearing potential: if engaging in heterosexual activity, agreement
             to use at least two adequate forms of contraception during the entire study and for 90
             days following the last dose of study drug

          -  For men: agreement to use contraceptive measures, and agreement to refrain from
             donating sperm

        Exclusion Criteria:

          -  Pregnancy or lactation (positive serum pregnancy test at screening or at admission)

          -  Any condition or disease detected during the medical interview/physical examination
             that would render the subject unsuitable for the study, place the subject at undue
             risk or interfere with the ability of the subject to complete the study in the opinion
             of the Investigator

          -  In the opinion of the Investigator, any major illness within 4 weeks prior to the
             screening examination or any febrile illness within 1 week prior to screening.

          -  History of any clinically significant, as determined by the investigator,
             gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric,
             cardiovascular, endocrinological, hematological, lymphatic, musculoskeletal,
             genitourinary, immunological, dermatological, or connective tissue or allergic
             disease, metabolic disorder, or cancer

          -  Signs and symptoms potentially indicative of peripheral neuropathy

          -  History or evidence of any medical condition potentially altering the absorption,
             distribution, metabolism, or elimination of drugs

          -  A history of clinically significant in the opinion of the Investigator
             hypersensitivity

          -  History or presence of clinically significant ECG abnormalities before study drug
             administration

          -  Clinically significant abnormalities in laboratory test results

          -  History of coagulopathies, bleeding disorders, or blood dyscrasias

          -  Current suicidal risk, in the opinion of the Investigator

          -  Unexplained syncope during the 6 months prior to screening or with presyncopal and/or
             syncopal symptoms during orthostatic challenge testing

          -  Current smoker or user of tobacco or nicotine-containing products or subjects who have
             smoked or used tobacco or nicotine-containing products within 3 months prior to first
             study drug administration

          -  Suspicion of or presence of a clinically relevant history of or current alcohol and/or
             other substance abuse or addiction.

          -  Alcohol consumption of &gt;14 units per week for males and females

          -  Positive urine alcohol test or urine drug screen at screening or Day -1 of any
             treatment period

          -  Hormone replacement therapy if postmenopausal status cannot be ascertained from
             medical history or FSH levels

          -  Clinically relevant deviation from normal in the physical examination including vital
             signs, as determined by the investigator

          -  Positive result for HIV 1, HIV 2, hepatitis C virus antibody, or hepatitis B core
             (HBc) antibody.

          -  Participation in an investigational drug or device study within 4 weeks or 5 times the
             elimination half-life, whichever is longer, prior to first dosing, or within 5 months
             prior to first administration of study drug in case of a study with a biological, as
             calculated from the day of Follow-up visit from the previous study

          -  Donation of blood or plasma or significant blood loss within 3 months prior to
             screening

          -  Dietary restrictions that would prohibit the consumption of standardized meals or the
             highfat, high-calorie meal planned for this study

          -  Use of any prohibited medications or food before study start or subjects who do not
             agree to refrain from consuming prohibited medications or food during the study

          -  Conditions requiring concomitant medication during the study (including for dental
             conditions).

          -  Any prescribed systemic or topical medication within 4 weeks (or within 5 times the
             elimination half-life of the medication, whichever is longer) of the first
             administration of study drug

          -  Used any nonprescribed systemic or topical medication or herbal remedies within 7 days
             before the first study drug administration

          -  Received any medications known to chronically alter drug absorption or elimination
             processes within 4 weeks before the first administration of study drug

          -  Use of any drugs or substances, including herbal treatments such as St John's wort,
             that are known to be substrates, inducers, or inhibitors of CYP3A4 within 4 weeks
             before the first administration of study drug

          -  Use of any drugs or substances, including herbal treatments, such as fluoxetine,
             fluvoxamine, aspirin, norethisterone, rifampicin, etc that are known to be substrates,
             inducers, or inhibitors of CYP2C19 within 4 weeks before the first administration of
             study drug

          -  Subjects under judicial supervision, guardianship, or curatorship

          -  Poor venous access for blood sampling

          -  Participants who are intolerant to sucrose

          -  Previous exposure to balovaptan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International Clinical Pharmacology Center (EDS US Clinic)</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

